Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review)
- Authors:
- Xiangxiang Lei
- Xiaoge Hu
- Qiliang Lu
- Wen Fu
- Wen Sun
- Qiancheng Ma
- Dongsheng Huang
- Qiuran Xu
-
Affiliations: Institute of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang 310053, P.R. China, The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China, Qingdao Medical College, Qingdao University, Qingdao, Shandong 266000, P.R. China, Second Clinical Medical Institute, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China, Institute of Bioengineering, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, P.R. China - Published online on: February 13, 2023 https://doi.org/10.3892/or.2023.8500
- Article Number: 63
-
Copyright: © Lei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Grady WM, Yu M and Markowitz SD: Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer. Gastroenterology. 160:690–709. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Joshi SS and Badgwell BD: Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 71:264–279. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021. View Article : Google Scholar : PubMed/NCBI | |
|
Park W, Chawla A and O'Reilly EM: Pancreatic cancer: A review. JAMA. 326:851–862. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
US Preventive Services Task Force, . Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW Jr, et al: Screening for pancreatic cancer: US Preventive Services Task Force Reaffirmation Recommendation statement. JAMA. 322:438–444. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sirica AE, Strazzabosco M and Cadamuro M: Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res. 149:321–387. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Song X, Hu Y, Li Y, Shao R, Liu F and Liu Y: Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 5:2302020. View Article : Google Scholar : PubMed/NCBI | |
|
Reichenbach ZW, Murray MG, Saxena R, Farkas D, Karassik EG, Klochkova A, Patel K, Tice C, Hall TM, Gang J, et al: Clinical and translational advances in esophageal squamous cell carcinoma. Adv Cancer Res. 144:95–135. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Popovic D, Vucic D and Dikic I: Ubiquitination in disease pathogenesis and treatment. Nat Med. 20:1242–1253. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cockram PE, Kist M, Prakash S, Chen SH, Wertz IE and Vucic D: Ubiquitination in the regulation of inflammatory cell death and cancer. Cell Death Differ. 28:591–605. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda F: Ubiquitin conjugating enzymes in the regulation of the autophagy-dependent degradation pathway. Matrix Biol. 100–101. 23–29. 2021.PubMed/NCBI | |
|
Hershko A and Ciechanover A: The ubiquitin system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Tang X, Qi X, Fu X, Ghimire S, Ma R, Li S, Zhang N and Si H: The ubiquitin conjugating enzyme: An important ubiquitin transfer platform in ubiquitin-proteasome system. Int J Mol Sci. 21:28942020. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Y and Rape M: Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol. 10:755–764. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hofmann RM and Pickart CM: In vitro assembly and recognition of Lys-63 polyubiquitin chains. J Biol Chem. 276:27936–27943. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Park J, Cho J and Song EJ: Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 43:1144–1161. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bui QT, Hong JH, Kwak M, Lee JY and Lee PC: Ubiquitin-Conjugating Enzymes in Cancer. Cells. 10:13832021. View Article : Google Scholar : PubMed/NCBI | |
|
Du X, Song H, Shen N, Hua R and Yang G: The molecular basis of ubiquitin-conjugating enzymes (E2s) as a potential target for cancer therapy. Int J Mol Sci. 22:34402021. View Article : Google Scholar : PubMed/NCBI | |
|
van Wijk SJ and Timmers HT: The family of ubiquitin-conjugating enzymes (E2s): Deciding between life and death of proteins. FASEB J. 24:981–993. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wiener R, DiBello AT, Lombardi PM, Guzzo CM, Zhang X, Matunis MJ and Wolberger C: E2 ubiquitin-conjugating enzymes regulate the deubiquitinating activity of OTUB1. Nat Struct Mol Biol. 20:1033–1039. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Stewart MD, Ritterhoff T, Klevit RE and Brzovic PS: E2 enzymes: More than just middle men. Cell Res. 26:423–440. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hosseini SM, Okoye I, Chaleshtari MG, Hazhirkarzar B, Mohamadnejad J, Azizi G, Hojjat-Farsangi M, Mohammadi H, Shotorbani SS and Jadidi-Niaragh F: E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions. Clin Chim Acta. 498:126–134. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gehrke SG, Riedel HD, Herrmann T, Hadaschik B, Bents K, Veltkamp C and Stremmel W: UbcH5A, a member of human E2 ubiquitin-conjugating enzymes, is closely related to SFT, a stimulator of iron transport, and is up-regulated in hereditary hemochromatosis. Blood. 101:3288–3293. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Wang L, Xu X, Sun H and Wu L: LncRNA HLA Complex Group 11 knockdown alleviates cisplatin resistance in gastric cancer by targeting the miR-144-3p/UBE2D1 Axis. Cancer Manag Res. 13:7543–7557. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Xie H, He Y, Wu Y and Lu Q: Silencing of UBE2D1 inhibited cell migration in gastric cancer, decreasing ubiquitination of SMAD4. Infect Agent Cancer. 16:632021. View Article : Google Scholar : PubMed/NCBI | |
|
Bergink S and Jentsch S: Principles of ubiquitin and SUMO modifications in DNA repair. Nature. 458:461–467. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shen JD, Fu SZ, Ju LL, Wang YF, Dai F, Liu ZX, Ji HZ, Shao JG and Bian ZL: High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma. Oncol Lett. 15:7362–7368. 2018.PubMed/NCBI | |
|
Tokumoto M, Fujiwara Y, Shimada A, Hasegawa T, Seko Y, Nagase H and Satoh M: Cadmium toxicity is caused by accumulation of p53 through the down-regulation of Ube2d family genes in vitro and in vivo. J Toxicol Sci. 36:191–200. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Saville MK, Sparks A, Xirodimas DP, Wardrop J, Stevenson LF, Bourdon JC, Woods YL and Lane DP: Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem. 279:42169–42181. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou C, Bi F, Yuan J, Yang F and Sun S: Gain of UBE2D1 facilitates hepatocellular carcinoma progression and is associated with DNA damage caused by continuous IL-6. J Exp Clin Cancer Res. 37:2902018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang A, Ding X, Demarque M, Liu X, Pan D, Xin H, Zhong B, Wang X, Dejean A, Jin W and Dong C: Ubc9 is required for positive selection and late-stage maturation of thymocytes. J Immunol. 198:3461–3470. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta MK, McLendon PM, Gulick J, James J, Khalili K and Robbins J: UBC9-mediated sumoylation favorably impacts cardiac function in compromised hearts. Circ Res. 118:1894–1905. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Z, Tan X, Zhao A, Zhu L, Yin B, Yuan J, Qiang B and Peng X: microRNA-214-mediated UBC9 expression in glioma. BMB Rep. 45:641–646. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu S, Sachdeva M, Wu F, Lu Z and Mo YY: Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene. 29:1763–1772. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fang S, Qiu J, Wu Z, Bai T and Guo W: Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin. Oncotarget. 8:49783–49795. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai CL, Liu WL, Hsu FM, Yang PS, Yen RF, Tzen KY, Cheng AL, Chen PJ and Cheng JC: Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice. Hepatology. 67:586–599. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Gao S, Chen J and Lou W: UBE2I promotes metastasis and correlates with poor prognosis in hepatocellular carcinoma. Cancer Cell Int. 20:2342020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang XK, Liao XW, Zhou X, Han CY, Chen ZJ, Yang CK, Huang JL, Wang JY, Liu JQ, Huang HS, et al: Oncogene UBE2I enhances cellular invasion, migration and proliferation abilities via autophagy-related pathway resulting in poor prognosis in hepatocellular carcinoma. Am J Cancer Res. 10:4178–4197. 2020.PubMed/NCBI | |
|
Reyes-Hernandez OD, Mejia-Garcia A, Sanchez-Ocampo EM, Cabañas-Cortés MA, Ramírez P, Chávez-González L, Gonzalez FJ and Elizondo G: Ube2l3 gene expression is modulated by activation of the aryl hydrocarbon receptor: Implications for p53 ubiquitination. Biochem Pharmacol. 80:932–940. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Whitcomb EA, Dudek EJ, Liu Q and Taylor A: Novel control of S phase of the cell cycle by ubiquitin-conjugating enzyme H7. Mol Biol Cell. 20:1–9. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tao NN, Zhang ZZ, Ren JH, Zhang J, Zhou YJ, Wai Wong VK, Kwan Law BY, Cheng ST, Zhou HZ, Chen WX, et al: Overexpression of ubiquitin-conjugating enzyme E2 L3 in hepatocellular carcinoma potentiates apoptosis evasion by inhibiting the GSK3β/p65 pathway. Cancer Lett. 481:1–14. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dikshit A, Jin YJ, Degan S, Hwang J, Foster MW, Li CY and Zhang JY: UBE2N promotes melanoma growth via MEK/FRA1/SOX10 signaling. Cancer Res. 78:6462–6472. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang E, Liu Q, Wang Y, Wang H, He L, Jin X and Li N: MicroRNA miR-147b promotes tumor growth via targeting UBE2N in hepatocellular carcinoma. Oncotarget. 8:114072–114080. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shang M, Weng L, Xu G, Wu S, Liu B, Yin X, Mao A, Zou X and Wang Z: TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. J Cell Physiol. 236:6868–6883. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Shekhar MP, Gerard B, Pauley RJ, Williams BO and Tait L: Rad6B is a positive regulator of beta-catenin stabilization. Cancer Res. 68:1741–1750. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Huang WL, Luo CW, Chou CL, Yang CC, Chen TJ, Li CF and Pan MR: High expression of UBE2B as a Poor prognosis factor in patients with rectal cancer following chemoradiotherapy. Anticancer Res. 40:6305–6317. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M and Nakagawara A: UbcH10 Is the Cancer-related E2 Ubiquitin-conjugating Enzyme. Cancer Res. 63:4167–4173. 2003.PubMed/NCBI | |
|
Zhang H, Zhao G, Ke B, Ma G, Liu GL, Liang H, Liu LR and Hao XS: Overexpression of UBE2C correlates with poor prognosis in gastric cancer patients. Eur Rev Med Pharmacol Sci. 22:1665–1671. 2018.PubMed/NCBI | |
|
Wang Y, Huang F, Liu M and Zhao Q: UBE2C mRNA expression controlled by miR-300 and HuR determines its oncogenic role in gastric cancer. Biochem Biophys Res Commun. 534:597–603. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Han T, Wei G and Wang Y: Inhibition of microRNA-17/20a suppresses cell proliferation in gastric cancer by modulating UBE2C expression. Oncol Rep. 33:2529–2536. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang R, Song Y, Liu X, Wang Q, Wang Y, Li L, Kang C and Zhang Q: UBE2C induces EMT through Wnt/β-catenin and PI3K/Akt signaling pathways by regulating phosphorylation levels of Aurora-A. Int J Oncol. 50:1116–1126. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang M, Qu Y, Shi R, Wu X, Su C, Hu Z, Chang Q, Liu S, Pan G, Lei M, et al: Ubiquitin-conjugating enzyme UbcH10 promotes gastric cancer growth and is a potential biomarker for gastric cancer. Oncol Rep. 36:779–786. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K, Inoue H, Kuwano H and Mori M: Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 121:33–38. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu M, Wu M, Bian S, Song Q, Xiao M, Huang H, You L, Zhang J, Zhang J, Cheng C, et al: DNA primase subunit 1 deteriorated progression of hepatocellular carcinoma by activating AKT/mTOR signaling and UBE2C-mediated P53 ubiquitination. Cell Biosci. 11:422021. View Article : Google Scholar : PubMed/NCBI | |
|
Wei Z, Liu Y, Qiao S, Li X, Li Q, Zhao J, Hu J, Wei Z, Shan A, Sun X and Xu B: Identification of the potential therapeutic target gene UBE2C in human hepatocellular carcinoma: An investigation based on GEO and TCGA databases. Oncol Lett. 17:5409–5418. 2019.PubMed/NCBI | |
|
Xiong Y, Lu J, Fang Q, Lu Y, Xie C, Wu H and Yin Z: UBE2C functions as a potential oncogene by enhancing cell proliferation, migration, invasion, and drug resistance in hepatocellular carcinoma cells. Biosci Rep. 39:BSR201823842019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou W, Xu J, Tan M, Li H, Li H, Wei W and Sun Y: UBE2M is a stress-inducible dual E2 for neddylation and ubiquitylation that promotes targeted degradation of UBE2F. Mol Cell. 70:1008–1024. e62018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang GC, Yu XN, Sun JL, Xiong J, Yang YJ, Jiang XM and Zhu JM: UBE2M promotes cell proliferation via the β-catenin/cyclin D1 signaling in hepatocellular carcinoma. Aging (Albany NY). 12:2373–2392. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang B, Deng C, Wang L, Zhou F, Zhang S, Kang W, Zhan P, Chen J, Shen S, Guo H, et al: Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway. Mol Carcinog. 57:201–215. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chang R, Wei L, Lu Y, Cui X, Lu C, Liu L, Jiang D, Xiong Y, Wang G, Wan C and Qian H: Upregulated expression of ubiquitin-conjugating enzyme E2Q1 (UBE2Q1) is associated with enhanced cell proliferation and poor prognosis in human hapatocellular carcinoma. J Mol Histol. 46:45–56. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hu N, Fan XP, Fan YC, Chen LY, Qiao CY, Han LY and Wang K: Hypomethylated ubiquitin-conjugating enzyme2 Q1 (UBE2Q1) gene promoter in the serum is a promising biomarker for hepatitis B Virus-associated hepatocellular carcinoma. Tohoku J Exp Med. 242:93–100. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Yin L, Yang L, Zheng Y, Liu S, Yang J, Cui H and Wang H: Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma. FEBS J. 286:4889–4909. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Qi S, Guan X, Zhang J, Yu D, Yu X, Li Q, Yin W, Cheng XD, Zhang W and Qin JJ: Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis. Mol Cancer. 21:702022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen S, Chen Y, Hu C, Jing H, Cao Y and Liu X: Association of clinicopathological features with UbcH10 expression in colorectal cancer. J Cancer Res Clin Oncol. 136:419–426. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fujita T, Ikeda H, Taira N, Hatoh S, Naito M and Doihara H: Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer. BMC Cancer. 9:872009. View Article : Google Scholar : PubMed/NCBI | |
|
Cacciola NA, Calabrese C, Malapelle U, Pellino G, De Stefano A, Sepe R, Sgariglia R, Quintavalle C, Federico A, Bianco A, et al: UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients. Mol Carcinog. 55:793–807. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li SZ, Song Y, Zhang HH, Jin BX, Liu Y, Liu WB, Zhang XD and Du RL: UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer. Sci Rep. 4:69102014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen SM, Jiang CY, Wu JY, Liu B, Chen YJ, Hu CJ and Liu XX: RNA interference-mediated silencing of UBCH10 gene inhibits colorectal cancer cell growth in vitro and in vivo. Clin Exp Pharmacol Physiol. 37:525–529. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Tian S, Li X, Ji Y, Wang Z and Liu C: UBE2C promotes rectal carcinoma via miR-381. Cancer Biol Ther. 19:230–238. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bavi P, Uddin S, Ahmed M, Jehan Z, Bu R, Abubaker J, Sultana M, Al-Sanea N, Abduljabbar A, Ashari LH, et al: Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. Am J Pathol. 178:2109–2120. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shafiee SM, Seghatoleslam A, Nikseresht M, Hosseini SV, Alizadeh-Naeeni M, Safaei A and Owji AA: UBE2Q1 expression in human colorectal tumors and cell lines. Mol Biol Rep. 40:7045–7051. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fahmidehkar MA, Shafiee SM, Eftekhar E, Mahbudi L and Seghatoleslam A: Induction of cell proliferation, clonogenicity and cell accumulation in S phase as a consequence of human UBE2Q1 overexpression. Oncol Lett. 12:2169–2174. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shafiee S, Seghatoleslam A, Nikseresht M, Hosseini SV, Alizadeh-Naeeni M, Safaei A and Owji AA: Expression status of UBE2Q2 in colorectal primary tumors and cell lines. Iran J Med Sci. 39 (Suppl 2):S196–S202. 2014.PubMed/NCBI | |
|
Mokarram P, Shakiba-Jam F, Kavousipour S, Sarabi MM and Seghatoleslam A: Promoter methylation status of two novel human genes, UBE2Q1 and UBE2Q2, in colorectal cancer: A new finding in Iranian patients. Asian Pac J Cancer Prev. 16:8247–8252. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shen T, Cai LD, Liu YH, Li S, Gan WJ, Li XM, Wang JR, Guo PD, Zhou Q, Lu XX, et al: Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes metastasis of colorectal cancer by epigenetically suppressing autophagy. J Hematol Oncol. 11:952018. View Article : Google Scholar : PubMed/NCBI | |
|
Washiro M, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Sugimoto T, Seki N and Miyazaki M: Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: A potential chemotherapeutic target. J Cancer Res Clin Oncol. 134:793–801. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Gao C, Shi D, Mao J, Zhao J, Guo L, Guo J and Jiao Z: Knockdown of Nedd8conjugating enzyme UBE2M suppresses the proliferation and induces the apoptosis of intrahepatic cholangiocarcinoma cells. Oncol Rep. 42:2670–2679. 2019.PubMed/NCBI | |
|
Wang X, Li G, Luo Q and Gan C: Identification of crucial genes associated with esophageal squamous cell carcinoma by gene expression profile analysis. Oncol Lett. 15:8983–8990. 2018.PubMed/NCBI | |
|
Dastsooz H, Cereda M, Donna D and Oliviero S: A comprehensive bioinformatics analysis of UBE2C in cancers. Int J Mol Sci. 20:22282019. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Xie Y, Wang X, Jiang C, Yuan X, Zhang A, Yang L, Liu C, Zou H, Li F and Hu J: Identification of hub genes associated with esophageal cancer progression using bioinformatics analysis. Oncol Lett. 20:2142020. View Article : Google Scholar : PubMed/NCBI | |
|
Matsumoto A, Ishibashi Y, Urashima M, Omura N, Nakada K, Nishikawa K, Shida A, Takada K, Kashiwagi H and Yanaga K: High UBCH10 protein expression as a marker of poor prognosis in esophageal squamous cell carcinoma. Anticancer Res. 34:955–961. 2014.PubMed/NCBI | |
|
Li R, Pang XF, Huang ZG, Yang LH, Peng ZG, Ma J and He RQ: Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis. BMC Cancer. 21:9962021. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Li X, Wang W, Gao T and Shi Z: UBE2C is involved in the functions of ECRG4 on esophageal squamous cell carcinoma. Biomed Pharmacother. 98:201–206. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wu J, Tian B, Yang J, Huo H, Song Z, Yu J and Gu Y: Reduction of Hip2 suppresses gastric cancer cell proliferation, migration, invasion and tumorigenesis. Transl Cancer Res. 9:774–785. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D'Andrea AD and Dutta A: UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 23:589–596. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Xiang P, Pan Q, Huang Y, Xie N and Zhu W: Ubiquitin-Conjugating Enzyme E2T is an independent prognostic factor and promotes gastric cancer progression. Tumour Biol. 37:11723–11732. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Luo C, Yao Y, Yu Z, Zhou H, Guo L, Zhang J, Cao H, Zhang G, Li Y and Jiao Z: UBE2T knockdown inhibits gastric cancer progression. Oncotarget. 8:32639–32654. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Z, Jiang X, Qin L, Deng H, Wang J, Ren W, Li H, Zhao L, Liu H, Yan H, et al: A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene. 40:1027–1042. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Garnett MJ, Mansfeld J, Godwin C, Matsusaka T, Wu J, Russell P, Pines J and Venkitaraman AR: UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit. Nat Cell Biol. 11:1363–1369. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang CY and Yang M: Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis. World J Hepatol. 14:956–971. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Pan YH, Yang M, Liu LP, Wu DC, Li MY and Su SG: UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma. Biochem Biophys Res Commun. 503:895–902. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ma Y, Li K, Li S, Liang B, Liu Q and Mo Z: Prognostic value of ubiquitin-conjugating enzyme E2 S overexpression in hepatocellular carcinoma. Int J Biol Macromol. 119:225–231. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gui L, Zhang S, Xu Y, Zhang H, Zhu Y and Kong L: UBE2S promotes cell chemoresistance through PTEN-AKT signaling in hepatocellular carcinoma. Cell Death Discov. 7:3572021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao X, Weng W, Jin M, Li S, Chen Q, Li B, Zhou Z, Lan C and Yang Y: Identification of biomarkers based on bioinformatics analysis: The expression of ubiquitin-conjugating enzyme E2T (UBE2T) in the carcinogenesis and progression of hepatocellular carcinoma. Med Sci Monit. 27:e9290232021.PubMed/NCBI | |
|
Ren X, Li A, Ying E, Fang J, Li M and Yu J: Upregulation of ubiquitin-conjugating enzyme E2T (UBE2T) predicts poor prognosis and promotes hepatocellular carcinoma progression. Bioengineered. 12:1530–1542. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wei X, You X, Zhang J and Zhou C: MicroRNA-1305 inhibits the stemness of LCSCs and tumorigenesis by repressing the UBE2T-Dependent akt-signaling pathway. Mol Ther Nucleic Acids. 16:721–732. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu LL, Zhu JM, Yu XN, Zhu HR, Shi X, Bilegsaikhan E, Guo HY, Wu J and Shen XZ: UBE2T promotes proliferation via G2/M checkpoint in hepatocellular carcinoma. Cancer Manag Res. 11:8359–8370. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Guo J, Wang M, Wang J and Wu C: Ubiquitin-conjugating enzyme E2T knockdown suppresses hepatocellular tumorigenesis via inducing cell cycle arrest and apoptosis. World J Gastroenterol. 25:6386–6403. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu LP, Yang M, Peng QZ, Li MY, Zhang YS, Guo YH, Chen Y and Bao SY: UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53. Biochem Biophys Res Commun. 493:20–27. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tao Y, Li R, Shen C, Li J, Zhang Q, Ma Z, Wang F and Wang Z: SENP1 is a crucial promotor for hepatocellular carcinoma through deSUMOylation of UBE2T. Aging (Albany NY). 12:1563–1576. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q, Guo Z, Liu L and Wu D: UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. J Exp Clin Cancer Res. 39:2222020. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng YW, Gao PF, Ma MZ, Chen Y and Li CY: Role of ubiquitin-conjugating enzyme E2T in the carcinogenesis and progression of pancreatic cancer. Oncol Lett. 20:1462–1468. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Liang Y, Li P, Liang Q, Sun H, Xu D and Hu W: Oncogenic Activities Of UBE2S Mediated By VHL/HIF-1α /STAT3 Signal Via the ubiquitin-proteasome system In PDAC. Onco Targets Ther. 12:9767–9781. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Wang Y, Li Y, Yin W, Mo L, Qian X, Zhang Y, Wang G, Bu F, Zhang Z, et al: Ube2s stabilizes beta-Catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development. Cell Death Dis. 9:4562018. View Article : Google Scholar : PubMed/NCBI | |
|
Luo M and Zhou Y: Comprehensive analysis of differentially expressed genes reveals the promotive effects of UBE2T on colorectal cancer cell proliferation. Oncol Lett. 22:7142021. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Liu G, Liu R, He J, Wang G, Zhang H, Liu T, Bai J, Cheng N and Qiu J: Expression of ubiquitin-conjugating enzyme E2T in colorectal cancers and clinical implications. Oncol Lett. 20:2752020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu M, Li X, Huang W, Chen Y, Wang B and Liu X: Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal cancer progression by facilitating ubiquitination and degradation of p53. Clin Res Hepatol Gastroenterol. 45:1014932021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu X, Li T, Niu X, Chen L and Ge C: Identification of UBE2T as an independent prognostic biomarker for gallbladder cancer. Oncol Lett. 20:442020. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Wang H, Dong W, Cao ZY, Li R, Yang C, Cong WM, Dong H and Jin GZ: The diagnostic and prognostic value of UBE2T in intrahepatic cholangiocarcinoma. PeerJ. 8:e84542020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu F, Zhu C, Gao P, Zheng S and Li C: Ubiquitin-conjugating enzyme E2T regulates cell proliferation and migration in cholangiocarcinoma. Anticancer Drugs. 31:836–846. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Liu Y, Leng X, Cao K, Sun W, Zhu J and Ma J: UBE2T contributes to the prognosis of esophageal squamous cell carcinoma. Pathol Oncol Res. 27:6325312021. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Z, Liu R, Lu Q, Zeng Z, Liu Y, Zhao J, Liu X, Li L, Huang H, Yao Y, et al: UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKalpha2/mTOR pathway. Int J Med Sci. 18:3749–3758. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Shi X, Wang B, Chen X, Zheng Y, Ding Y and Wang C: Upregulation of ubiquitin-conjugating enzyme E2Z is associated with human hepatocellular carcinoma. Biochem Biophys Res Commun. 523:25–32. 2020. View Article : Google Scholar : PubMed/NCBI |
